Cardiorenal complications of immune checkpoint inhibitors

The development of immune checkpoint inhibitors (ICIs) has driven a revolutionary change in cancer treatment. Although traditional chemotherapeutic agents remain the first-line option for most cancers, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These ag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Nephrology 2018-09, Vol.14 (9), p.571-588
Hauptverfasser:	Sury, Krishna, Perazella, Mark A., Shirali, Anushree C.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/1438 631/443/592/75 631/67/1059/2325 692/4022/1585/2763 Animals Antibodies Antibodies, Monoclonal, Humanized - adverse effects Antigens Antineoplastic Agents, Immunological - adverse effects Autoantibodies Autoimmunity B7-H1 Antigen - antagonists & inhibitors Biological markers Cancer Cancer cells Cancer therapies Cancer treatment Cell death Chemotherapy Clinical trials CTLA-4 Antigen - antagonists & inhibitors Gene mutation Heart Diseases - chemically induced Heart Diseases - diagnosis Heart Diseases - therapy Humans Immune response Immune system Immunotherapy Ipilimumab - adverse effects Kidney diseases Kidney Diseases - chemically induced Kidney Diseases - therapy Kidneys Lymphocytes Medical research Medicine Medicine & Public Health Myocarditis Neoplasms - drug therapy Neoplasms - immunology Nephritis Nephrology Nivolumab - adverse effects Programmed Cell Death 1 Receptor - antagonists & inhibitors Protein binding Proteins Review Article Signal Transduction - drug effects Surface science T cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!